Email this article 
Urticaria is not a sentence. The clinical cases
- Authors: Danilycheva IV1, Shulzhenko AE1, Bondarenko NG1
-
Affiliations:
- Institute of Immunology
- Issue: Vol 13, No 2 (2016)
- Pages: 23-26
- Section: Articles
- URL: https://rusalljournal.ru/raj/article/view/374
- DOI: https://doi.org/10.36691/RJA374
- ID: 374
Cite item
Open Access
Access granted
Abstract
Omalizumab - monoclonal therapeutic antibody to human IgE, is effectively used for the treatment of patients with chronic spontaneous urticaria (HSC), refractory to 4 times increased doses of antihistamines. The article describes two cases of effective treatment of patients (HSC) with omalizumab (Xolair® «Novartis Pharma» LLC) after a long period of unsuccessful therapy with H1-antihistamines, leukotriene receptor antagonists, and corticosteroids.
Keywords
Full Text
About the authors
I V Danilycheva
Institute of Immunology
Email: ivdanilycheva@mail.ru
A E Shulzhenko
Institute of Immunology
N G Bondarenko
Institute of Immunology
References
- Федеральные клинические рекомендации по диагностике и лечению крапивницы. Российская ассоциация аллергологов и клинических иммунологов. Росс. Аллергол. Журн. 2011, № 1, с. 38-46.
- Zuberbier Т., Aberer W., Asero R. EAACI/GA2LEN/EDF/ WAO urticaria guideline for the definition, classification, diagnosis, and management of urticaria:the 2013 revision and update. Allergy. 2014.
- Maurer M., Weller K., Bindslev-Jensen C. et al. Unmet clinical needsin chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011, v. 66, p. 317-330.
- Martin Metz, Tatevik Ohanyan, Martin K. Church et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014, v. 73, p. 57-62.
- Saini S., Rosen K.E., Hsieh H.J. et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2011, v. 128, p. 567-573.
- Maurer M., Rosen K.E., Hsieh H.J. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 2013, v. 368 (10), p. 924-935.
- NHS England. Specialised Services Circular. NICE Technology Appraisal 339: Omalizumab for previously treated chronic spontaneous urticaria. 10 August 2015.
- Daut V. et al. HNO 2012, v. 60 (5), p. 457-465.
- Xolair (omalizumab) 150 mg Solution for Injection Summary of product Characteristics. Novartis Pharmaceuticals UK Ltd. Updated 7th July 2015.
- Zuberbier T. et al. Allergy. 2014, v. 69 (7), p. 868-887.
Supplementary files
